secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001104659-24-076936
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec COO Adrian Haigh departs; 66,667 options accelerated at $8.03
--------------------------------------------------------------------

- Adrian Haigh left COO role effective June 30, 2024; joined as COO Aug 2023 after nine years as independent director.
- Separation agreement accelerates vesting of options for 66,667 common shares at $8.03, expiring June 30, 2027.
- Company actively searching for a U.S.-based leader to replace Haigh.
- Haigh cited timing after Norgine licensing deal and U.S. commercial strategy refocus as reasons to step down.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924076936/0001104659-24-076936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924076936/tm2418676d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-076936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer